BORIANI, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 105.994
EU - Europa 57.314
AS - Asia 44.582
SA - Sud America 7.895
AF - Africa 903
OC - Oceania 396
Continente sconosciuto - Info sul continente non disponibili 63
Totale 217.147
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 104.270
SE - Svezia 21.003
SG - Singapore 14.151
GB - Regno Unito 10.998
CN - Cina 10.798
IT - Italia 7.275
BR - Brasile 6.520
HK - Hong Kong 6.340
VN - Vietnam 4.577
DE - Germania 3.418
FI - Finlandia 3.166
PL - Polonia 3.161
TR - Turchia 2.081
UA - Ucraina 1.911
RU - Federazione Russa 1.681
FR - Francia 1.637
BD - Bangladesh 1.415
KR - Corea 1.194
BG - Bulgaria 887
IN - India 751
CA - Canada 621
ID - Indonesia 606
NL - Olanda 499
AR - Argentina 463
JP - Giappone 463
BZ - Belize 402
MX - Messico 388
AU - Australia 374
IQ - Iraq 364
ES - Italia 266
AE - Emirati Arabi Uniti 264
IE - Irlanda 261
AT - Austria 252
PK - Pakistan 242
ZA - Sudafrica 225
EC - Ecuador 189
CO - Colombia 185
UZ - Uzbekistan 154
VE - Venezuela 153
MA - Marocco 148
CL - Cile 127
LT - Lituania 116
MY - Malesia 104
PH - Filippine 103
CZ - Repubblica Ceca 102
SA - Arabia Saudita 102
JO - Giordania 98
EG - Egitto 97
KE - Kenya 94
BE - Belgio 92
TN - Tunisia 81
NP - Nepal 80
AZ - Azerbaigian 78
CH - Svizzera 76
RO - Romania 76
DZ - Algeria 73
PY - Paraguay 71
TH - Thailandia 70
TW - Taiwan 69
IL - Israele 66
BO - Bolivia 64
JM - Giamaica 63
PE - Perù 60
UY - Uruguay 59
KZ - Kazakistan 52
PT - Portogallo 48
RS - Serbia 48
GE - Georgia 46
DO - Repubblica Dominicana 45
IR - Iran 45
GR - Grecia 44
CR - Costa Rica 43
OM - Oman 39
BY - Bielorussia 36
EU - Europa 36
AL - Albania 33
HR - Croazia 32
DK - Danimarca 31
TT - Trinidad e Tobago 31
SN - Senegal 30
LB - Libano 28
PA - Panama 27
KG - Kirghizistan 26
ET - Etiopia 25
BH - Bahrain 24
HU - Ungheria 23
PS - Palestinian Territory 23
QA - Qatar 23
SI - Slovenia 22
SK - Slovacchia (Repubblica Slovacca) 21
BA - Bosnia-Erzegovina 19
MD - Moldavia 19
AO - Angola 18
NG - Nigeria 18
NZ - Nuova Zelanda 18
GT - Guatemala 17
HN - Honduras 17
NO - Norvegia 17
CY - Cipro 16
CI - Costa d'Avorio 14
Totale 216.828
Salva come PNG Salva come JPEG
Città #
Stockholm 18.326
Fairfield 12.855
Ashburn 10.527
Singapore 9.179
Woodbridge 7.524
Santa Clara 7.397
Southend 7.258
Hong Kong 6.176
Houston 5.921
Seattle 4.998
Cambridge 4.158
Wilmington 4.147
Chandler 4.145
San Jose 3.812
Jacksonville 3.670
Hefei 3.258
Warsaw 3.010
Helsinki 2.824
Ann Arbor 2.816
London 2.614
Dearborn 2.335
Beijing 2.057
New York 1.782
The Dalles 1.710
Council Bluffs 1.615
Modena 1.515
Nyköping 1.463
Ho Chi Minh City 1.401
Los Angeles 1.259
San Diego 1.258
Izmir 1.225
Chicago 1.154
Seoul 1.150
Hanoi 1.134
Princeton 893
Milan 866
Sofia 863
Dallas 807
Lauterbourg 792
Eugene 730
Buffalo 621
Moscow 534
São Paulo 526
Columbus 487
Jakarta 478
Boardman 459
Shanghai 444
Belize City 400
Salt Lake City 376
Rome 351
Atlanta 315
Bologna 308
Tokyo 301
Munich 272
Da Nang 266
Falls Church 257
Dublin 236
Frankfurt am Main 224
Nuremberg 216
Haiphong 211
Rio de Janeiro 211
Amsterdam 202
Toronto 193
Redondo Beach 190
Fremont 189
Guangzhou 177
Las Vegas 171
Perth 170
Saint Louis 169
Norwalk 163
Phoenix 157
Belo Horizonte 153
Orem 152
Kent 150
Miano 150
Lappeenranta 145
Albuquerque 140
Tampa 140
Tashkent 139
Brooklyn 135
Elk Grove Village 134
Baghdad 132
Kunming 132
Naples 131
Nanjing 120
Redwood City 120
Johannesburg 119
Montreal 118
Mexico City 113
Brasília 107
San Francisco 105
Curitiba 104
Philadelphia 103
Kilburn 100
Vienna 99
Amman 94
Dhaka 93
Florence 90
Miami 89
Paris 89
Totale 163.394
Salva come PNG Salva come JPEG
Nome #
'Pill-in-the-pocket' treatment for recent-onset atrial fibrillation [4] 2.649
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 2.485
'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: The EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry 2.461
'Real-world' atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase 2.414
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA) 2.160
12-year Temporal Trend in Referral Pattern and Test Results of Stress Echocardiography in a Tertiary Care Referral Center with Moderate Volume Activities and Cath-lab Facility 2.096
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 2.093
108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, The Netherlands. 2.079
11C-mHED for PET / CT: principles of synthesis, methodology and first clinical applications 2.075
'Real-World' antithrombotic treatment in atrial fibrillation: The eorp-af pilot survey 2.073
Long-Term Implications of Atrial Fibrillation in Patients With Degenerative Mitral Regurgitation 705
2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing 655
2018 EHRA expert consensus statement on lead extraction: Recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: Endorsed by APHRS/HRS/LAHRS 601
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) 583
A changing scenario in the clinical use of implantable defibrillators: the need for long-term data on lead performance. 536
La sindrome da pacemaker. 533
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC (Eur Heart J (2021) 42 (373–498) DOI: 10.1093/eurheartj/ehaa612) 520
Atrial Fibrillation in the Setting of Acute Pneumonia: Not a Secondary Arrhythmia 495
Linee guida AIAC all'impianto di pacemaker, dispositivi per la resincronizzazione cardiaca, defibrillatori automatici e loop recorder. Update 2011. 494
Screening for atrial fibrillation: A Report of the AF-SCREEN International Collaboration 482
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) 456
A prospective randomized evaluation of VV delay optimization in CRT patients. Proceedings 16th World Congress in Cardiac Electrophysiology and Cardiac Techniques 436
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation 424
Registro Italiano Pacemaker e Defibrillatori: Bollettino Periodico 2016 Associazione Italiana di Aritmologia e Cardiostimolazione 398
The future of continuing medical education: the roles of medical professional societies and the health care industry: Position paper prepared with contributions from the European Society of Cardiology Committees for Advocacy, Education and Industry Relations, Endorsed by the Board of the European Society of Cardiology 381
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) 366
Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol 356
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial 345
Prevalence and clinical significance of left bundle branch block according to classical or strict definition criteria in permanent pacemaker patients 344
Cardiac involvement in systemic sclerosis: identification of high-risk patient profiles in different patterns of clinical presentation 339
Guía de práctica clínica de la ESC 2013 sobre estimulación cardiaca y terapia de resincronización cardiaca 338
Home care for heart failure: can caregiver education prevent hospital admissions? A randomized trial in primary care 334
Radar-Based Monitoring of Vital Signs: A Tutorial Overview 332
QRS pattern and improvement in right and left ventricular function after cardiac resynchronization therapy: a radionuclide study 332
Cardiac device therapy in patients with left ventricular dysfunction and heart failure: ‘real-world’ data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital) 329
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 328
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report 328
Elevated TGF β2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes 327
P wave dispersion and short-term vs. late atrial fibrillation recurrences after cardioversion 326
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. 322
Impact of COVID-19 pandemic on the clinical activities related to arrhythmias and electrophysiology in Italy: results of a survey promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing) 316
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA) 314
Clinically guided pacemaker choice and setting: pacemaker expert programming study 307
Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden 307
Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes 307
European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics 304
Implantable cardioverter-defibrillator–computed respiratory disturbance index accurately identifies severe sleep apnea: The DASAP-HF study 303
Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-AF General Pilot Registry 303
Meta-analysis of clinical outcomes of electrical cardioversion and catheter ablation in patients with atrial fibrillation and chronic kidney disease 302
Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis 302
The 2018 European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Executive summary 298
Chronic kidney disease and arrhythmias: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference 297
New classification of geometric patterns considering left ventricular volume in patients with chronic aortic valve regurgitation: Prevalence and association with adverse cardiovascular outcomes 297
Role of the tricuspid regurgitation after mitraclip and transcatheter aortic valve implantation: a systematic review and meta-analysis 296
Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples 295
Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation 294
Implant rates of cardiac implantable electrical devices in Europe: A systematic literature review 294
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 293
Atrial fibrillation in dilated cardiomyopathy: Outcome prediction from an observational registry 293
Alcohol Intake and Risk of Hypertension: A Systematic Review and Dose-Response Meta-Analysis of Nonexperimental Cohort Studies 291
Rhythm discrimination by rate branch and QRS morphology in dual chamber implantable cardioverter defibrillators 291
Clinical and electrocardiographic characteristics at admission of COVID-19/SARS-CoV2 pneumonia infection 287
Emery-Dreifuss Muscular Dystrophy-Associated Mutant Forms of Lamin A Recruit the Stress Responsive Protein Ankrd2 into the Nucleus, Affecting the Cellular Response to Oxidative Stress 285
Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry 285
Beta-blocker treatment guided by head-up tilt test in neurally mediated syncope 285
Heart failure after myocardial revascularization: Risk markers 284
The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) Randomized Controlled Trial: Phase 1 Results on Dynamics of Early Intervention With Remote Monitoring 284
New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial 284
The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden 284
Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. 284
Combined use of morphology discrimination, sudden onset, and stability as discriminating algorithms in single chamber cardioverter defibrillators 283
EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation 283
The wearable cardioverter-defibrillator: Current technology and evolving indications 283
Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF 282
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 281
Decrease in patient radiation exposure by a tantalum filter during electrophysiological procedures. 280
Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA 278
Health economics and the European Heart Rhythm Association. 277
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy 277
Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation 277
A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial. 277
Management of cardiopulmonary disease in patients with systemic sclerosis: cardiorheumatology clinic and patient care standardization proposal 277
Percutaneous pericardiocentesis for pericardial effusion: predictors of mortality and outcomes 276
Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry 274
Cardiac resynchronization and implantable cardioverter defibrillator therapy: Preliminary results from the InSync Implantable Cardioverter Defibrillator Italian Registry 274
DIGItal Health Literacy after COVID-19 Outbreak among Frail and Non-Frail Cardiology Patients: The DIGI-COVID Study 273
Far-field R wave oversensing in dual-chamber pacemakers designed for atrial arrhythmia management: effect of pacing site and lead tip to ring distance 273
Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations 272
Prevention of long-lasting atrial fibrillation through antitachycardia pacing in DDDR pacemakers 272
Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry 271
The QRS interval in patients treated with resynchronization therapy: which value? 270
Letter by Gasparini and Boriani Regarding Article, "Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation: Results From the Resynchronization for Ambulatory Heart Failure Trial (RAFT)" 270
Health care cost analysis of enhanced pacing modalities in bradycardia patients: Portuguese case study on the results of the MINERVA trial 270
Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE 270
Beat-to-beat variability of P-wave in patients suffering from atrial fibrillation 270
Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. 269
The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2 269
Management of Phrenic Stimulation in CRT Patients over the Long Term: Still an Unmet Need ? 269
Implantable dual-chamber defibrillator for the selective treatment of spontaneous atrial and ventricular arrhythmias: arrhythmia incidence and device performance. 269
Outcomes with dronedarone in atrial fibrillation: What differences between real-world practice and trials? A meta-analysis and meta-regression analysis 268
Totale 52.430
Salva come PNG Salva come JPEG
Categoria #
all - tutte 826.147
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 826.147
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.071 0 0 0 0 0 0 0 0 0 0 0 1.071
2021/202215.465 664 1.848 1.677 712 427 1.286 887 786 1.655 1.369 2.411 1.743
2022/202311.536 1.660 974 714 826 1.469 1.536 259 1.187 1.758 206 597 350
2023/20249.853 393 632 435 803 2.283 1.440 447 1.696 223 253 327 921
2024/202533.713 1.151 386 730 1.788 4.911 5.146 3.766 2.148 4.150 2.542 3.045 3.950
2025/202680.026 3.554 1.887 5.259 4.812 5.374 9.122 9.842 3.735 24.539 4.807 5.986 1.109
Totale 220.317